Journal of Lipid Research, Vol 38, 2502-2515, Copyright © 1997 by Lipid Research, Inc.

ARTICLES

Attenuation of plasma low density lipoprotein cholesterol by select 3- hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors

CL Bisgaier, AD Essenburg, BJ Auerbach, ME Pape, CS Sekerke, A Gee, S Wolle and RS Newton
Department of Vascular and Cardiac Diseases, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA.

Low density lipoprotein (LDL) reduction independent of LDL receptor regulation was investigated using HMG-CoA reductase inhibitors in LDL receptor-deficient mice. In males, LDL cholesterol dose-dependently decreased with atorvastatin treatment after 1 week. As untreated mice grew older, their LDL cholesterol progressively rose above basal levels, but was quelled with atorvastatin treatment. In females, atorvastatin treatment time-dependently decreased LDL cholesterol levels and induced hepatic HMG-CoA reductase activity. Unlike males, cholesterol-lowering effects of the drug were sustained in females. Lovastatin, simvastatin, and pravastatin also reduced total and LDL cholesterol; however, additional studies in females demonstrated that atorvastatin caused the greatest dose-dependent and sustained effect after 2 weeks. In females, hepatic HMG-CoA reductase mRNA inversely correlated with LDL cholesterol lowering, with atorvastatin showing the greatest increase in mRNA levels (17.2-fold), followed by lovastatin (10.7-fold), simvastatin (4.1-fold), and pravastatin (2.5-fold). Atorvastatin effects on lipoprotein production were determined after acute (1 day) or chronic (2 week) treatment prior to intraperitoneal injection of Triton WR1339. Acute treatment reduced cholesterol (-29%) and apoB (-16%) secretion, with no change in triglyceride secretion. In contrast, chronic treatment elevated cholesterol (+20%), apoB (+31%), and triglyceride (+57%) secretion. Despite increased cholesterol and apoB secretion, plasma levels were reduced by 51% and 46%, respectively. Overall, under acute or chronic conditions, apoB paralleled cholesterol secretion rates, and triglyceride to cholesterol secretion ratios were elevated by 38% and 32%, respectively. We propose that atorvastatin limits cholesterol for lipoprotein assembly, which is compensated for by triglyceride enrichment. In addition, with either acute or chronic atorvastatin treatment, apoB-100 secretion was blocked, and compensated for by an increased secretion of apoB-48. The apoB-48 particles produced are cleared by LDL receptor-independent mechanisms, with an overall effect of reducing LDL production in these mice. These studies support the idea that HMG-CoA reductase inhibitors modulate lipoprotein levels independent of LDL receptors, and suggest they may have utility in hyperlipidemias caused by LDLreceptor disorders.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. M. Shachaf, O. D. Perez, S. Youssef, A. C. Fan, S. Elchuri, M. J. Goldstein, A. E. Shirer, O. Sharpe, J. Chen, D. J. Mitchell, et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis Blood, October 1, 2007; 110(7): 2674 - 2684. [Abstract] [Full Text] [PDF]

				S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra Mouse Models for Atherosclerosis and Pharmaceutical Modifiers Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1706 - 1721. [Abstract] [Full Text] [PDF]

				L. Erkkila, M. Jauhiainen, K. Laitinen, K. Haasio, T. Tiirola, P. Saikku, and M. Leinonen Effect of Simvastatin, an Established Lipid-Lowering Drug, on Pulmonary Chlamydia pneumoniae Infection in Mice Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3959 - 3962. [Abstract] [Full Text] [PDF]

				J. J. Repa, S. D. Turley, G. Quan, and J. M. Dietschy Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption J. Lipid Res., April 1, 2005; 46(4): 779 - 789. [Abstract] [Full Text] [PDF]

				C. T. Cramer, B. Goetz, K. L. M. Hopson, G. J. Fici, R. M. Ackermann, S. C. Brown, C. L. Bisgaier, W. G. Rajeswaran, D. C. Oniciu, and M. E. Pape Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome J. Lipid Res., July 1, 2004; 45(7): 1289 - 1301. [Abstract] [Full Text] [PDF]

				O. Aktas, S. Waiczies, A. Smorodchenko, J. Dorr, B. Seeger, T. Prozorovski, S. Sallach, M. Endres, S. Brocke, R. Nitsch, et al. Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through Atorvastatin J. Exp. Med., March 17, 2003; 197(6): 725 - 733. [Abstract] [Full Text] [PDF]

				H. D. Lieu, S. K. Withycombe, Q. Walker, J. X. Rong, R. L. Walzem, J. S. Wong, R. L. Hamilton, E. A. Fisher, and S. G. Young Eliminating Atherogenesis in Mice by Switching Off Hepatic Lipoprotein Secretion Circulation, March 11, 2003; 107(9): 1315 - 1321. [Abstract] [Full Text] [PDF]

				F. Bea, E. Blessing, B. Bennett, M. Levitz, E. P. Wallace, and M. E. Rosenfeld Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering Arterioscler. Thromb. Vasc. Biol., November 1, 2002; 22(11): 1832 - 1837. [Abstract] [Full Text] [PDF]

				G. C. Ness and C. M. Chambers Feedback and Hormonal Regulation of Hepatic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase: The Concept of Cholesterol Buffering Capacity Experimental Biology and Medicine, May 1, 2000; 224(1): 8 - 19. [Abstract] [Full Text]

				L. J. Wilcox, P. H. R. Barrett, and M. W. Huff Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin J. Lipid Res., June 1, 1999; 40(6): 1078 - 1089. [Abstract] [Full Text]

				R. G. Elkin, Z. Yan, Y. Zhong, S. S. Donkin, K. K. Buhman, J. A. Story, J. J. Turek, R. E. Porter Jr., M. Anderson, R. Homan, et al. Select 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Vary in Their Ability to Reduce Egg Yolk Cholesterol Levels in Laying Hens through Alteration of Hepatic Cholesterol Biosynthesis and Plasma VLDL Composition J. Nutr., May 1, 1999; 129(5): 1010 - 1019. [Abstract] [Full Text]

				Z. Zhang, K. Cianflone, and A. D. Sniderman Role of Cholesterol Ester Mass in Regulation of Secretion of ApoB100 Lipoprotein Particles by Hamster Hepatocytes and Effects of Statins on That Relationship Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 743 - 752. [Abstract] [Full Text] [PDF]